Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2

Opinion
Video

This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
Related Content
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
September 9th 2025
Podcast
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
September 9th 2025
Podcast
Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article
The trial’s primary end points were EFS and OS. Secondary end points included mPR rate, pCR rate, AEs, and quality of life.

Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups

Russ Conroy
September 9th 2025
Article